LPTN 2.68 Lpath Inc $LPTN Hit a 52 week low of 2.68 Closing the day 10:41 at 2.68 -0.10 -3.60% With a day low of 2.68 and a total volume of 18,586.
LPTN Recent Posts: http://investorshangout.com/Lpath-Inc-LPTN-63881/
LPTN Lpath Inc Recent Headline News
Lpath Announces Departure Of CEO
PR Newswire - Tue Nov 04, 3:30PM CST
Lpath, Inc. (NASDAQ: LPTN) announced today that Scott Pancoast has resigned as president, chief executive officer and a member of the board of directors, effective November 3. The board of directors has appointed biotechnology consultant Michael Lack as the company's interim chief executive officer while the board conducts a search for a new CEO.
LPTN: 2.60 (-0.18)
Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs
PR Newswire - Mon Oct 20, 7:00AM CDT
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, received official notification from the European Patent Office that the company has been granted another key patent supporting its iSONEP(TM) and ASONEP(TM) programs.
LPTN: 2.60 (-0.18)
Lpath, Inc. Announces Closing of $12.5 Million Registered Direct Offering
PR Newswire - Mon Sep 29, 7:30AM CDT
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, announced today the closing of its previously announced $12.5 million registered direct offering. As previously disclosed, Lpath sold 3,605,042 registered shares of common stock and warrants to purchase 3,605,042 unregistered shares of common stock in a registered direct offering at a purchase price of $3.475 per share-and-warrant-share combination. The warrants have an exercise price of $3.36 per underlying share, are immediately exercisable, and terminate on the five-year anniversary of issuance. Maxim Group LLC acted as the exclusive placement agent for the offering.
LPTN: 2.60 (-0.18)
Lpath to Present at the 13th Annual BIO Investor Forum
PR Newswire - Thu Sep 25, 3:05PM CDT
Lpath, Inc. (NASDAQ: LPTN) today announced that Scott Pancoast, president and CEO, will present at the 13th Annual BIO Investor Forum on Tuesday, October 7, 2014 at 8:30 a.m. PDT in San Francisco. Mr. Pancoast will provide an update on the company's lead product candidate, iSONEP(TM), currently in a Phase 2 trial (Nexus) to assess its efficacy for patients with wet age-related macular degeneration, and the ASONEP(TM) Phase 2a trial in patients with renal cell carcinoma. He will also discuss additional candidates Lpathomab(TM), an anti-LPA antibody that is expected to enter the clinic in early 2015 for neuropathic pain, and Altepan(TM), an anti-leukotriene antibody that is being studied in models of respiratory and inflammatory disease.
LPTN: 2.60 (-0.18)
Lpath, Inc. Announces $12.5 Million Registered Direct Offering
PR Newswire - Fri Sep 19, 7:30AM CDT
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, announced today that it has entered into definitive agreements to sell 3,605,042 registered shares of common stock and 3,605,042 unregistered warrants in a registered direct offering. The combined purchase price for one registered share of common stock and one unregistered warrant to purchase one unregistered share of common stock will be $3.475. The warrants have an exercise price of $3.36, are immediately exercisable and will terminate on the five-year anniversary of issuance. The closing of the offering is expected to occur on or about September 24, 2014, subject to the satisfaction of customary closing conditions.
LPTN: 2.60 (-0.18)
Nasdaq stocks posting largest volume increases
AP - Tue Aug 19, 5:09PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
RDEN: 18.11 (-0.39), HGSH: 4.17 (-0.05), BRID: 7.90 (unch), LNBB: 15.21 (-0.12), RAND: 3.10 (unch), IMCB: 20.00 (+0.31), AMCF: 1.98 (+0.02), LPTN: 2.60 (-0.18), JAXB: 11.90 (-0.01), PBCP: 10.25 (unch)
Lpath to Present at 34th Annual Canaccord Genuity Growth Conference
PR Newswire - Mon Aug 11, 7:00AM CDT
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, today announced that Scott Pancoast, president and CEO, will present at the 34th Annual Canaccord Genuity Growth Conference on Wednesday, August 13, 2014 at 5:00 p.m. Eastern Time in Boston. The live webcast presentation and replay will be available by visiting the Investor section of the Lpath website at www.Lpath.com.
LPTN: 2.60 (-0.18)
Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP
PR Newswire - Thu Jul 24, 7:00AM CDT
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, reported interim results in a Phase 2a single-arm, open-label trial where ASONEP(TM) is being investigated as a treatment for metastatic renal cell carcinoma (RCC) in patients that have failed at least one therapy involving a VEGF inhibitor (e.g., Sutent®/ sunitinib maleate) and no more than one mTOR inhibitor (e.g., Afinitor®/everolimus), with a maximum of three failed treatments in all. This patient population is considered "last line," and the literature suggests cancer progression in this population within a one-to-two month time frame.
LPTN: 2.60 (-0.18)
Global Choroidal Neovascularization (CNV) Market 2014-2018 with Bayer, F. Hoffmann-La Roche, Novartis & Regeneron Pharmaceuticals Dominating
M2 - Tue Jun 24, 5:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vbmxjk/global_choroidal) has announced the addition of the "Global Choroidal Neovascularization (CNV) Market 2014-2018" report to their offering. The current competition in the Global CNV market is strong as the available treatment options and marketed products have been successful in meeting the market requirement, while treating the underlying cause of the disease. The current market drugs include Lucentis, approved for CNV associated with wet AMD; Macugen, approved for CNV associated with wet AMD; and Visudyne, approved for CNV associated with wet AMD, presumed ocular histoplasmosis, and pathologic myopia. Apart from these, Avastin, which is currently used as an off-label drug has gradually captured a major share of the market. In addition, the CNV pipeline seems to be promising with various molecules in the development phase. These products are expected to meet the unmet needs in the market and will provide physicians with a wider choice in treating CNV. The Global CNV market is driven by several factors, of which high patient and physician satisfaction is one of the major drivers. High patient and physician satisfaction has resulted in increased demand for CNV treatment therapies. Further, the report states that one of the major challenges is the high cost of treatment. Many patients do not have the required budget for investing in high cost treatment options. Key Vendors - Bayer AG - F. Hoffmann-La Roche Ltd. - Novartis AG - Regeneron Pharmaceuticals Inc. Other Prominent Vendors - Affitech A/S - Allergan Inc. - Chengdu Kanghong Biotech Co. Ltd. - Gilead Sciences Inc. - Lpath Inc. - Mat Biopharma SAS - Pfizer Inc. - Promedior Inc. - QLT Inc. - Quark Pharmaceuticals Inc. - Resolvyx Pharmaceuticals Inc. - Sanwa Kagaku Kenkyusho Co. Ltd. - Valeant Pharmaceuticals International Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Product Profiles - Market Research Methodology - Introduction - Market Landscape - Product Portfolio of Current CNV Therapies - Clinical Pipeline Portpolio - Rate of Incidence and Prevalence - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape For more information visit http://www.researchandmarkets.com/research/vb..._choroidal
AGN: 196.69 (+1.35), QLTI: 3.96 (unch), GILD: 106.80 (-1.21), PFE: 30.37 (+0.05), LPTN: 2.60 (-0.18), REGN: 398.92 (+0.56), VRX.TO: 147.36 (+0.05), NVS: 92.76 (-0.01)
Renal Cell Carcinoma - Pipeline Review, H1 2014
M2 - Thu Jun 12, 3:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5lwrwg/renal_cell) has announced the addition of the "Renal Cell Carcinoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Cell Carcinoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Renal Cell Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Renal Cell Carcinoma and enlists all their major and minor projects Companies Mentioned: - Bristol-Myers Squibb - Boehringer Ingelheim - Kyowa Hakko Kirin - Amgen - Eli Lilly and Company - GlaxoSmithKline - Seattle Genetics - Genentech - Agenus - Merck & Co - Celltrion - Astellas Pharma - ImmunoGen - Ono - Pfizer - Taiho - Onyx - Bayer - Advaxis - Hemispherx - Celldex Therapeutics, Inc. - Active Biotech AB - Lorus Therapeutics Inc. - Lpath, Inc. - Bionomics Limited - Flamel Technologies S.A. - Mologen AG - Threshold Pharmaceuticals, Inc. - Colby Pharmaceutical Company - Wilex AG For more information visit http://www.researchandmarkets.com/research/5lwrwg/renal_cell
CLDX: 14.41 (-0.05), AMGN: 161.42 (-1.00), LLY: 67.52 (-0.33), BMY: 58.49 (-0.23), GSK: 45.66 (-0.30), LPTN: 2.60 (-0.18), FLML: 11.96 (+0.17), MRK: 59.26 (-0.11)
3 Stocks Under $10 to Watch
at The Street - Mon Mar 17, 6:40AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
FSM: 4.40 (-0.02), LPTN: 2.60 (-0.18), SA: 6.64 (+0.12)
New Published Paper Shows Efficacy of Lpath's Anti-LPA Antibody, Lpathomab, in Traumatic Brain Injury Models
PR Newswire - Wed Mar 05, 6:30AM CST
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, has brought scientists one step closer to finding a potential treatment for traumatic brain injury (TBI) with a recent publication showing that Lpathomab(TM), a therapeutic antibody, reverses much of the damage caused by trauma to the nervous system.
LPTN: 2.60 (-0.18)
Lpath to Present at Upcoming Roth Investor Conference
PR Newswire - Tue Mar 04, 7:00AM CST
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, today announced that Scott Pancoast, president and CEO, will be presenting at the 26th Annual Roth Conference being held March 10 -12, 2014 in Laguna Niguel, Calif. Mr. Pancoast is scheduled to present on March 11, 2014 at 4:30 p.m. PST/7:30 p.m. EST. The presentation will be webcast live and will be available for replay on the Lpath, Inc. corporate website at www.Lpath.com.
LPTN: 2.60 (-0.18)
Lpath Granted Key U.S. Patent Related to Ocular Drug Program, iSONEP
PR Newswire - Wed Jan 22, 6:30AM CST
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, received official notification from the U.S. Patent and Trademark Office that the company has been issued another key patent supporting its iSONEP(TM) program. The newly issued U.S. patent, No. 8,614,103, is entitled, "Compositions and Methods for Treating Ocular Conditions." It claims methods of using monoclonal antibodies (including iSONEP) that bind sphingosine-1-phosphate (S1P) in the treatment of a wide variety of ocular conditions, including wet age-related macular degeneration (AMD).
LPTN: 2.60 (-0.18), VZ: 50.93 (+0.32)
FEPSGA Games - Herbalist, Others Enjoy Trade Boom in Makurdi
All Africa Global Media - Wed Dec 18, 4:41AM CST
A herbalist selling traditional medicines at the venue of the ongoing Federal Public Service Games Association (FEPSGA) Games in Makurdi says he is enjoying high patronage.
UNXL: 5.53 (+0.06), ETH: 28.92 (+0.09), VGZ: 0.31 (unch), LPTN: 2.60 (-0.18)
Macular Degeneration - Pipeline Review, H2 2013 Gives an Overview of Pipeline Products for Macular Degeneration
M2 - Wed Sep 04, 12:19PM CDT
Research and Markets (http://www.researchandmarkets.com/research/wv3x9q/macular) has announced the addition of the "Macular Degeneration - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Macular Degeneration - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Macular Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Macular Degeneration. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Macular Degeneration. - A review of the Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Macular Degeneration pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 Alcon, Inc. Genzyme Corporation Johnson & Johnson F. Hoffmann-La Roche Ltd. Bausch & Lomb Incorporated Allergan, Inc. Shionogi & Co., Ltd. pSivida Corp. Advanced Cell Technology, Inc. GlaxoSmithKline plc Genentech, Inc. Quark Pharmaceuticals, Inc. Pfizer Inc. iCo Therapeutics Inc. Lpath, Inc. Mesoblast Ltd BioDiem Ltd Summit Corporation plc ThromboGenics NV PolyMedix, Inc. e-Therapeutics plc NanoCarrier Co., Ltd. R-Tech Ueno, Ltd. Intellect Neurosciences, Inc. Omeros Corporation Angstrom Pharmaceuticals, Inc. Targa Therapeutics Corp. Pfenex Inc. SelectX Pharmaceuticals, Inc. Icon Bioscience, Inc. EyeGene, Inc. Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/wv3x9q/macula About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
PFE: 30.37 (+0.05), GSK: 45.66 (-0.30), LPTN: 2.60 (-0.18), OMER: 18.96 (-0.09), AGN: 196.69 (+1.35), JNJ: 108.55 (-0.36)
OTC Daily Alert Stock Watch - Lpath, Inc., (NASDAQ: LPTN)
WorldStockWire - Fri Aug 30, 12:15AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
LPTN: 2.60 (-0.18)
Nasdaq stocks posting largest percentage increases
AP - Mon Jul 29, 5:27PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
MWIV: 155.26 (+0.26), URRE: 2.45 (-0.06), SYNM: 3.35 (-0.04), INPH: 2.66 (-0.27), GCBC: 25.32 (-2.40), CZFC: 12.25 (+0.25), SPEX: 1.45 (+0.01), LPTN: 2.60 (-0.18)
LPTN Recent Posts: http://investorshangout.com/Lpath-Inc-LPTN-63881/
LPTN Lpath Inc Recent Headline News
Lpath Announces Departure Of CEO
PR Newswire - Tue Nov 04, 3:30PM CST
Lpath, Inc. (NASDAQ: LPTN) announced today that Scott Pancoast has resigned as president, chief executive officer and a member of the board of directors, effective November 3. The board of directors has appointed biotechnology consultant Michael Lack as the company's interim chief executive officer while the board conducts a search for a new CEO.
LPTN: 2.60 (-0.18)
Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs
PR Newswire - Mon Oct 20, 7:00AM CDT
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, received official notification from the European Patent Office that the company has been granted another key patent supporting its iSONEP(TM) and ASONEP(TM) programs.
LPTN: 2.60 (-0.18)
Lpath, Inc. Announces Closing of $12.5 Million Registered Direct Offering
PR Newswire - Mon Sep 29, 7:30AM CDT
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, announced today the closing of its previously announced $12.5 million registered direct offering. As previously disclosed, Lpath sold 3,605,042 registered shares of common stock and warrants to purchase 3,605,042 unregistered shares of common stock in a registered direct offering at a purchase price of $3.475 per share-and-warrant-share combination. The warrants have an exercise price of $3.36 per underlying share, are immediately exercisable, and terminate on the five-year anniversary of issuance. Maxim Group LLC acted as the exclusive placement agent for the offering.
LPTN: 2.60 (-0.18)
Lpath to Present at the 13th Annual BIO Investor Forum
PR Newswire - Thu Sep 25, 3:05PM CDT
Lpath, Inc. (NASDAQ: LPTN) today announced that Scott Pancoast, president and CEO, will present at the 13th Annual BIO Investor Forum on Tuesday, October 7, 2014 at 8:30 a.m. PDT in San Francisco. Mr. Pancoast will provide an update on the company's lead product candidate, iSONEP(TM), currently in a Phase 2 trial (Nexus) to assess its efficacy for patients with wet age-related macular degeneration, and the ASONEP(TM) Phase 2a trial in patients with renal cell carcinoma. He will also discuss additional candidates Lpathomab(TM), an anti-LPA antibody that is expected to enter the clinic in early 2015 for neuropathic pain, and Altepan(TM), an anti-leukotriene antibody that is being studied in models of respiratory and inflammatory disease.
LPTN: 2.60 (-0.18)
Lpath, Inc. Announces $12.5 Million Registered Direct Offering
PR Newswire - Fri Sep 19, 7:30AM CDT
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, announced today that it has entered into definitive agreements to sell 3,605,042 registered shares of common stock and 3,605,042 unregistered warrants in a registered direct offering. The combined purchase price for one registered share of common stock and one unregistered warrant to purchase one unregistered share of common stock will be $3.475. The warrants have an exercise price of $3.36, are immediately exercisable and will terminate on the five-year anniversary of issuance. The closing of the offering is expected to occur on or about September 24, 2014, subject to the satisfaction of customary closing conditions.
LPTN: 2.60 (-0.18)
Nasdaq stocks posting largest volume increases
AP - Tue Aug 19, 5:09PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
RDEN: 18.11 (-0.39), HGSH: 4.17 (-0.05), BRID: 7.90 (unch), LNBB: 15.21 (-0.12), RAND: 3.10 (unch), IMCB: 20.00 (+0.31), AMCF: 1.98 (+0.02), LPTN: 2.60 (-0.18), JAXB: 11.90 (-0.01), PBCP: 10.25 (unch)
Lpath to Present at 34th Annual Canaccord Genuity Growth Conference
PR Newswire - Mon Aug 11, 7:00AM CDT
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, today announced that Scott Pancoast, president and CEO, will present at the 34th Annual Canaccord Genuity Growth Conference on Wednesday, August 13, 2014 at 5:00 p.m. Eastern Time in Boston. The live webcast presentation and replay will be available by visiting the Investor section of the Lpath website at www.Lpath.com.
LPTN: 2.60 (-0.18)
Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP
PR Newswire - Thu Jul 24, 7:00AM CDT
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, reported interim results in a Phase 2a single-arm, open-label trial where ASONEP(TM) is being investigated as a treatment for metastatic renal cell carcinoma (RCC) in patients that have failed at least one therapy involving a VEGF inhibitor (e.g., Sutent®/ sunitinib maleate) and no more than one mTOR inhibitor (e.g., Afinitor®/everolimus), with a maximum of three failed treatments in all. This patient population is considered "last line," and the literature suggests cancer progression in this population within a one-to-two month time frame.
LPTN: 2.60 (-0.18)
Global Choroidal Neovascularization (CNV) Market 2014-2018 with Bayer, F. Hoffmann-La Roche, Novartis & Regeneron Pharmaceuticals Dominating
M2 - Tue Jun 24, 5:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vbmxjk/global_choroidal) has announced the addition of the "Global Choroidal Neovascularization (CNV) Market 2014-2018" report to their offering. The current competition in the Global CNV market is strong as the available treatment options and marketed products have been successful in meeting the market requirement, while treating the underlying cause of the disease. The current market drugs include Lucentis, approved for CNV associated with wet AMD; Macugen, approved for CNV associated with wet AMD; and Visudyne, approved for CNV associated with wet AMD, presumed ocular histoplasmosis, and pathologic myopia. Apart from these, Avastin, which is currently used as an off-label drug has gradually captured a major share of the market. In addition, the CNV pipeline seems to be promising with various molecules in the development phase. These products are expected to meet the unmet needs in the market and will provide physicians with a wider choice in treating CNV. The Global CNV market is driven by several factors, of which high patient and physician satisfaction is one of the major drivers. High patient and physician satisfaction has resulted in increased demand for CNV treatment therapies. Further, the report states that one of the major challenges is the high cost of treatment. Many patients do not have the required budget for investing in high cost treatment options. Key Vendors - Bayer AG - F. Hoffmann-La Roche Ltd. - Novartis AG - Regeneron Pharmaceuticals Inc. Other Prominent Vendors - Affitech A/S - Allergan Inc. - Chengdu Kanghong Biotech Co. Ltd. - Gilead Sciences Inc. - Lpath Inc. - Mat Biopharma SAS - Pfizer Inc. - Promedior Inc. - QLT Inc. - Quark Pharmaceuticals Inc. - Resolvyx Pharmaceuticals Inc. - Sanwa Kagaku Kenkyusho Co. Ltd. - Valeant Pharmaceuticals International Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Product Profiles - Market Research Methodology - Introduction - Market Landscape - Product Portfolio of Current CNV Therapies - Clinical Pipeline Portpolio - Rate of Incidence and Prevalence - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape For more information visit http://www.researchandmarkets.com/research/vb..._choroidal
AGN: 196.69 (+1.35), QLTI: 3.96 (unch), GILD: 106.80 (-1.21), PFE: 30.37 (+0.05), LPTN: 2.60 (-0.18), REGN: 398.92 (+0.56), VRX.TO: 147.36 (+0.05), NVS: 92.76 (-0.01)
Renal Cell Carcinoma - Pipeline Review, H1 2014
M2 - Thu Jun 12, 3:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5lwrwg/renal_cell) has announced the addition of the "Renal Cell Carcinoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Cell Carcinoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Renal Cell Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Renal Cell Carcinoma and enlists all their major and minor projects Companies Mentioned: - Bristol-Myers Squibb - Boehringer Ingelheim - Kyowa Hakko Kirin - Amgen - Eli Lilly and Company - GlaxoSmithKline - Seattle Genetics - Genentech - Agenus - Merck & Co - Celltrion - Astellas Pharma - ImmunoGen - Ono - Pfizer - Taiho - Onyx - Bayer - Advaxis - Hemispherx - Celldex Therapeutics, Inc. - Active Biotech AB - Lorus Therapeutics Inc. - Lpath, Inc. - Bionomics Limited - Flamel Technologies S.A. - Mologen AG - Threshold Pharmaceuticals, Inc. - Colby Pharmaceutical Company - Wilex AG For more information visit http://www.researchandmarkets.com/research/5lwrwg/renal_cell
CLDX: 14.41 (-0.05), AMGN: 161.42 (-1.00), LLY: 67.52 (-0.33), BMY: 58.49 (-0.23), GSK: 45.66 (-0.30), LPTN: 2.60 (-0.18), FLML: 11.96 (+0.17), MRK: 59.26 (-0.11)
3 Stocks Under $10 to Watch
at The Street - Mon Mar 17, 6:40AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
FSM: 4.40 (-0.02), LPTN: 2.60 (-0.18), SA: 6.64 (+0.12)
New Published Paper Shows Efficacy of Lpath's Anti-LPA Antibody, Lpathomab, in Traumatic Brain Injury Models
PR Newswire - Wed Mar 05, 6:30AM CST
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, has brought scientists one step closer to finding a potential treatment for traumatic brain injury (TBI) with a recent publication showing that Lpathomab(TM), a therapeutic antibody, reverses much of the damage caused by trauma to the nervous system.
LPTN: 2.60 (-0.18)
Lpath to Present at Upcoming Roth Investor Conference
PR Newswire - Tue Mar 04, 7:00AM CST
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, today announced that Scott Pancoast, president and CEO, will be presenting at the 26th Annual Roth Conference being held March 10 -12, 2014 in Laguna Niguel, Calif. Mr. Pancoast is scheduled to present on March 11, 2014 at 4:30 p.m. PST/7:30 p.m. EST. The presentation will be webcast live and will be available for replay on the Lpath, Inc. corporate website at www.Lpath.com.
LPTN: 2.60 (-0.18)
Lpath Granted Key U.S. Patent Related to Ocular Drug Program, iSONEP
PR Newswire - Wed Jan 22, 6:30AM CST
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, received official notification from the U.S. Patent and Trademark Office that the company has been issued another key patent supporting its iSONEP(TM) program. The newly issued U.S. patent, No. 8,614,103, is entitled, "Compositions and Methods for Treating Ocular Conditions." It claims methods of using monoclonal antibodies (including iSONEP) that bind sphingosine-1-phosphate (S1P) in the treatment of a wide variety of ocular conditions, including wet age-related macular degeneration (AMD).
LPTN: 2.60 (-0.18), VZ: 50.93 (+0.32)
FEPSGA Games - Herbalist, Others Enjoy Trade Boom in Makurdi
All Africa Global Media - Wed Dec 18, 4:41AM CST
A herbalist selling traditional medicines at the venue of the ongoing Federal Public Service Games Association (FEPSGA) Games in Makurdi says he is enjoying high patronage.
UNXL: 5.53 (+0.06), ETH: 28.92 (+0.09), VGZ: 0.31 (unch), LPTN: 2.60 (-0.18)
Macular Degeneration - Pipeline Review, H2 2013 Gives an Overview of Pipeline Products for Macular Degeneration
M2 - Wed Sep 04, 12:19PM CDT
Research and Markets (http://www.researchandmarkets.com/research/wv3x9q/macular) has announced the addition of the "Macular Degeneration - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Macular Degeneration - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Macular Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Macular Degeneration. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Macular Degeneration. - A review of the Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Macular Degeneration pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 Alcon, Inc. Genzyme Corporation Johnson & Johnson F. Hoffmann-La Roche Ltd. Bausch & Lomb Incorporated Allergan, Inc. Shionogi & Co., Ltd. pSivida Corp. Advanced Cell Technology, Inc. GlaxoSmithKline plc Genentech, Inc. Quark Pharmaceuticals, Inc. Pfizer Inc. iCo Therapeutics Inc. Lpath, Inc. Mesoblast Ltd BioDiem Ltd Summit Corporation plc ThromboGenics NV PolyMedix, Inc. e-Therapeutics plc NanoCarrier Co., Ltd. R-Tech Ueno, Ltd. Intellect Neurosciences, Inc. Omeros Corporation Angstrom Pharmaceuticals, Inc. Targa Therapeutics Corp. Pfenex Inc. SelectX Pharmaceuticals, Inc. Icon Bioscience, Inc. EyeGene, Inc. Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/wv3x9q/macula About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
PFE: 30.37 (+0.05), GSK: 45.66 (-0.30), LPTN: 2.60 (-0.18), OMER: 18.96 (-0.09), AGN: 196.69 (+1.35), JNJ: 108.55 (-0.36)
OTC Daily Alert Stock Watch - Lpath, Inc., (NASDAQ: LPTN)
WorldStockWire - Fri Aug 30, 12:15AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
LPTN: 2.60 (-0.18)
Nasdaq stocks posting largest percentage increases
AP - Mon Jul 29, 5:27PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
MWIV: 155.26 (+0.26), URRE: 2.45 (-0.06), SYNM: 3.35 (-0.04), INPH: 2.66 (-0.27), GCBC: 25.32 (-2.40), CZFC: 12.25 (+0.25), SPEX: 1.45 (+0.01), LPTN: 2.60 (-0.18)
